Sonrotoclax hits 52.4% ORR in MCL, already backing an FDA accelerated approval
The Phase I/II abstract confirms the data behind BEQALZI's May 2026 approval, but PFS of 6.5 months trails the durability bar BeOne will need to defend at confirmatory review.
Executive Summary
- The abstract publishes the full Phase I/II dataset behind sonrotoclax's May 2026 FDA accelerated approval in relapsed/refractory mantle cell lymphoma: ORR-IRC of 52.4% against a 30% historic control, P<.0001. This is confirmatory publication of already-approved data, not a new efficacy signal, and it lets investors see the trial's actual result quality for the first time in full detail.
- Median PFS-IRC came in at 6.5 months while median duration of response reached 15.8 months, a split the abstract does not reconcile. That gap matters because BeOne's mandatory confirmatory trial, CELESTIAL-RRMCL, must demonstrate durable benefit to convert the accelerated approval into a full one.
- The registry shows three primary completion date changes and three enrollment revisions over the trial's life, an Unstable stability label. This history should temper confidence in how cleanly the disclosed 320 mg dataset maps to the trial as originally registered.
- The model's pre-readout endpoint-met probability of 95.7% carried low internal confidence (0.0161) and rested mainly on operational-design features like country count and endpoint window rather than mechanism-specific signals. The outcome confirmed the directional call, but the underlying confidence was weak.
The publication
A peer-reviewed abstract published July 1, 2026 discloses the complete Phase I/II results of NCT05471843, a 125-patient, single-arm, open-label trial of sonrotoclax monotherapy in BTK inhibitor-pretreated relapsed/refractory mantle cell lymphoma. In the 103 efficacy-evaluable patients who received the 320 mg target dose, the overall response rate by independent review committee reached 52.4% (95% CI, 42.4 to 62.4), a statistically significant increase over the historic control rate of 30% (P<.0001). The complete response rate was 15.5%, and responses held up in the TP53-mutant subgroup at 59.1%. This is not new efficacy news: BeOne disclosed the same topline result on August 29, 2025, and presented it at ASH on December 7, 2025. The abstract is the confirmatory scientific publication of data the FDA has already acted on.
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What's at stake
The FDA granted accelerated approval to sonrotoclax, branded BEQALZI, for adult relapsed/refractory MCL on May 13, 2026, built on this same Phase I/II dataset, after granting Breakthrough Therapy Designation and Priority Review and accepting the program into Project Orbis. Accelerated approval carries a mandatory confirmatory trial obligation, and BeOne is running CELESTIAL-RRMCL (NCT06742996), a Phase 3 study of sonrotoclax plus zanubrutinib versus placebo plus zanubrutinib, with a primary completion date around August 2028. Whether that trial converts the accelerated approval to full approval now depends on durability data the abstract only partially resolves.
The durability question
Median duration of response by IRC reached 15.8 months, but median progression-free survival by IRC was only 6.5 months, and median overall survival was not reached. The gap between a long duration of response and a shorter median PFS is not explained in the disclosed abstract; it likely reflects the roughly half of patients who never respond and progress earlier, pulling down the PFS median even as responders hold their responses. Safety was consistent with prior sonrotoclax disclosures: neutropenia (35.7% all-grade, 19.1% grade 3 or higher), thrombocytopenia (24.3%/9.6%), and anemia (24.3%/7.8%) were the most common adverse events, and tumor lysis syndrome occurred in 7.0% of patients, all resolving without sequelae.
Competitive and protocol context
Sonrotoclax is not first-in-class in BCL2-targeted MCL therapy; BeOne's own Phase 3 combination trial and a landscape of 17 BCL2 x MCL trials across 13 sponsors already exist. That landscape is rated 'challenging,' with a 67% historical Phase 1 failure rate for the BCL2 x MCL pairing and three sponsors that have already failed in it. The registered trial itself carries an 'Unstable' protocol-stability label: three primary completion date changes moved the date from March 2024 out to July 18, 2025, alongside three separate enrollment revisions, over 3.52 registry changes per year. None of that instability appears to have affected the underlying 320 mg efficacy data, but it is a reminder that the trial's registered structure moved considerably before the dataset now published was locked.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.